Rucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.
Amy M. Lugo, PharmD, BCPS, BC-ADM
Advertisement
Articles by Amy M. Lugo, PharmD, BCPS, BC-ADM
Advertisement
Latest Updated Articles
The Role of PARP Inhibitors in Treating Ovarian CancerPublished: April 30th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
FDA Approves Gazyva for Active Lupus Nephritis
3
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
4
Alongside Vaccines, Provide OTC Counseling Tips During Respiratory Virus Season
5
